Management Team Of Amarillo Biosciences, Discuss Upcoming Studies And Successful Passing Of FDA’s 30-day Review Process For Company’s Investigational New Drug Application For Idiopathic Pulmonary Fibrosis At SmallCapVoice.com

AUSTIN, Texas--(BUSINESS WIRE)--Aug. 17, 2006--SmallCapVoice.com, Inc. today announced that a new audio interview is available at SmallCapVoice.com. The featured guests are Joseph and Marty Cummins of Amarillo Biosciences (OTCBB:AMAR). The interview focuses on the recent news that the Company’s Investigational New Drug application (IND) for idiopathic pulmonary fibrosis (IPF) has successfully passed the FDA’s 30-day review process and has been allowed to go into effect. The interview can be heard here at http://www.smallcapvoice.com/amar/amar-8-16-06.html.

MORE ON THIS TOPIC